EDITORIAL
Published on 28 Mar 2023
Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
doi 10.3389/fonc.2023.1180650
- 796 views
- 2 citations
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Inhibitors of CDK family: New Perspective and Rationale for Drug Combination in Preclinical Model of Solid Tumors
Inhibitors of CDK family: New Perspective and Rationale for Drug Combination in Preclinical Model of Solid Tumors
9,631
Total downloads
30k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 03 Feb 2023
Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy
doi 10.3389/fphar.2023.970457
- 3,512 views
- 5 citations
REVIEW
Published on 19 Jan 2023
Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
doi 10.3389/fonc.2023.1095219
- 2,730 views
- 1 citation
ORIGINAL RESEARCH
Published on 08 Aug 2022
Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941
doi 10.3389/fphar.2022.958443
- 3,129 views
- 25 citations
REVIEW
Published on 08 Aug 2022
Review: Precise sarcoma patient-derived orthotopic xenograft (PDOX) mouse models enable identification of novel effective combination therapies with the cyclin-dependent kinase inhibitor palbociclib: A strategy for clinical application
doi 10.3389/fonc.2022.957844
- 2,077 views
- 11 citations
ORIGINAL RESEARCH
Published on 22 Jul 2022
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
doi 10.3389/fonc.2022.942341
- 3,070 views
- 16 citations
ORIGINAL RESEARCH
Published on 13 Jul 2022
Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
doi 10.3389/fonc.2022.903536
- 3,387 views
- 5 citations
ORIGINAL RESEARCH
Published on 25 May 2022
Tizoxanide Promotes Apoptosis in Glioblastoma by Inhibiting CDK1 Activity
doi 10.3389/fphar.2022.895573
- 2,327 views
- 12 citations
ORIGINAL RESEARCH
Published on 08 Apr 2022
CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
doi 10.3389/fonc.2022.819003
- 1,617 views
- 2 citations
ORIGINAL RESEARCH
Published on 22 Feb 2022
Adapalene Inhibits Prostate Cancer Cell Proliferation In Vitro and In Vivo by Inducing DNA Damage, S-phase Cell Cycle Arrest, and Apoptosis
doi 10.3389/fphar.2022.801624
- 3,152 views
- 12 citations
Published in
Frontiers in Oncology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore